| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/14740338.2017.1323864 |
| P698 | PubMed publication ID | 28441904 |
| P50 | author | Luis Puig | Q42669207 |
| P2093 | author name string | A Laiz | |
| A López-Ferrer | |||
| P2860 | cites work | Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38989105 |
| Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). | Q40705952 | ||
| Spondyloarthropathy: interleukin 23 and disease modification | Q41203599 | ||
| Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. | Q41454181 | ||
| Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial | Q46467386 | ||
| Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients | Q46753645 | ||
| Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. | Q50906224 | ||
| Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. | Q51821980 | ||
| Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla | Q30760660 | ||
| Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. | Q31140425 | ||
| Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas | Q33659249 | ||
| Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. | Q33823950 | ||
| Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). | Q34092442 | ||
| Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials | Q34189897 | ||
| Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) | Q36968787 | ||
| Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). | Q37465550 | ||
| Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review | Q38034394 | ||
| A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial | Q38390071 | ||
| Drug safety evaluation of apremilast for treating psoriatic arthritis | Q38397948 | ||
| New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol | Q38622082 | ||
| European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update | Q38661777 | ||
| Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis | Q38702419 | ||
| Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis | Q38958215 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 733-742 | |
| P577 | publication date | 2017-04-25 | |
| P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
| P1476 | title | The safety of ustekinumab for the treatment of psoriatic arthritis | |
| P478 | volume | 16 |
| Q90339285 | British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults |
| Q49722360 | Cutaneous Manifestations of Reactions to Biologics |
| Q47230622 | Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study |
| Q94554524 | Erythema multiforme after initiation of anti interleukin-12/23 (ustekinumab) treatment for plaque psoriasis |
| Q90397147 | Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges |
| Q98460557 | The risk of respiratory tract infections and interstitial lung disease with IL-12/23 and IL-23 antagonists in patients with autoimmune diseases: a systematic review and meta-analysis |
| Q96953884 | Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors |
| Q64226421 | Update in treatment of uveitic macular edema |
Search more.